# Numerical Simulation and Optimization of Drug-Coated Balloon Inflation for Vascular Stenosis

**Authors:** Chenzhao Zhang, Yuanyuan Zhang, Shengzhang Wang

PMC · DOI: 10.3390/bioengineering13030301 · Bioengineering · 2026-03-05

## TL;DR

This study uses computer simulations to determine the best balloon inflation times for drug-coated balloons in arteries with different levels of blockage.

## Contribution

The study introduces a numerical model to optimize DCB dilation time for varying stenosis levels based on drug transfer and diffusion.

## Key findings

- Longer balloon dilation time increases paclitaxel entry into the vessel wall.
- Paclitaxel concentration decreases over time after balloon withdrawal.
- Optimal dilation times for 10%, 30%, and 50% stenosis are 20 s, 60 s, and 80 s, respectively.

## Abstract

This study establishes a numerical model for the implantation of drug-coated balloons (DCBs) in blood vessels, in order to quantify drug (paclitaxel) transfer and diffusion within stenotic vessels and provide a reference for clinical surgical plans. Objective: To study the change in paclitaxel concentration over time in the blood vessel after the implantation of a DCB in vessels with different degrees of stenosis, and thereby determine the optimal balloon dilation time. Method: Using finite element modeling and numerical simulation techniques, a model was established to study the rules of paclitaxel concentration change over time in vessels with different degrees of stenosis. Results: Based on the simulation prediction, the longer the balloon dilation time during implantation, the more paclitaxel enters the vessel wall. After the balloon is withdrawn, the paclitaxel gradually diffuses evenly throughout the vessel, and the paclitaxel concentration gradually decreases over time. Conclusion: Under the simulation conditions, the optimal balloon dilation times for vessels with stenosis rates of 10%, 30%, and 50% should be 20 s, 60 s, and 80 s, corresponding effective duration of 6 weeks, 6 weeks and 4 weeks, respectively.

## Linked entities

- **Chemicals:** paclitaxel (PubChem CID 36314)

## Full-text entities

- **Diseases:** Vascular Stenosis (MESH:D003251)
- **Chemicals:** DCB (-), paclitaxel (MESH:D017239)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023489/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13023489/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023489/full.md

---
Source: https://tomesphere.com/paper/PMC13023489